Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 12-Month Low Following Analyst Downgrade

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Thursday after Needham & Company LLC lowered their price target on the stock from $30.00 to $27.00. Needham & Company LLC currently has a buy rating on the stock. Day One Biopharmaceuticals traded as low as $6.26 and last traded at $6.30, with a volume of 3859708 shares trading hands. The stock had previously closed at $6.99.

A number of other analysts have also commented on the company. HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Wedbush reissued an "outperform" rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a report on Tuesday, March 25th. JPMorgan Chase & Co. lowered their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. Finally, Bank of America decreased their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $30.57.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares in the company, valued at $1,531,059.40. This represents a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the completion of the transaction, the chief financial officer now directly owns 252,638 shares in the company, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,064 shares of company stock worth $251,925 in the last three months. Corporate insiders own 6.20% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of DAWN. GF Fund Management CO. LTD. bought a new position in Day One Biopharmaceuticals in the 4th quarter worth $27,000. R Squared Ltd bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter worth about $31,000. Pallas Capital Advisors LLC purchased a new stake in shares of Day One Biopharmaceuticals during the first quarter worth about $87,000. Wealth Enhancement Advisory Services LLC bought a new stake in Day One Biopharmaceuticals during the 1st quarter valued at approximately $88,000. Finally, Exchange Traded Concepts LLC boosted its stake in Day One Biopharmaceuticals by 19.6% in the 1st quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company's stock worth $117,000 after purchasing an additional 2,407 shares during the period. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Stock Performance

The firm has a market capitalization of $638.53 million, a PE ratio of -6.12 and a beta of -1.24. The business's fifty day simple moving average is $7.77 and its 200-day simple moving average is $11.21.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. Sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.